Meeting
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.
Authors
Mary L. Disis
University of Washington, Seattle, WA
Mary L. Disis , Manish R. Patel , Shubham Pant , Erika Paige Hamilton , Albert C. Lockhart , Karen Kelly , J. Thaddeus Beck , Michael S. Gordon , Glen J. Weiss , Matthew H. Taylor , Jorge Chaves , Alain C. Mita , Kevin M. Chin , Anja von Heydebreck , Jean-Marie Cuillerot , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5533)
DOI
10.1200/JCO.2016.34.15_suppl.5533
Abstract #
5533
Poster Bd #
356
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.
First Author: Andrea B. Apolo
Poster
2017 Genitourinary Cancers Symposium
Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial.
First Author: Manish R. Patel
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
First Author: Claire F. Verschraegen
Poster
2018 ASCO Annual Meeting
Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.
First Author: Arun Rajan